Last reviewed · How we verify
Anakinra (Kineret)
At a glance
| Generic name | Kineret |
|---|---|
| Also known as | IL-1 receptor inhibitor, Anakinra, anakinra, interleukin-1 receptor antagonist |
| Sponsor | Biovitrum Ab |
| Drug class | Interleukin-1 Receptor Antagonist |
| Target | Interleukin-1 receptor, type I |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2001 |
Approved indications
- COVID19 pneumonia requiring supplemental oxygen
- Chronic infantile neurological, cutaneous and articular syndrome
- Cryopyrin associated periodic syndrome
- Familial Mediterranean fever
- Rheumatoid arthritis
- Still's disease
Common side effects
- Injection site reaction
- Infection
- Worsening of rheumatoid arthritis
- Upper respiratory tract infection
- Headache
- Nausea
- Diarrhea
- Sinusitis
- Arthralgia
- Flu-like symptoms
- Abdominal pain
- Vomiting
Serious adverse events
- Serious infection
- Serious infection in asthma patients
- Cellulitis
- Pneumonia
- Bone and joint infections
Key clinical trials
- Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS (PHASE2,PHASE3)
- IL-1 Inhibition in Early TNBC (PHASE2)
- IL1 Inhibition in FOP
- Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma (PHASE2)
- Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease (EARLY_PHASE1)
- Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke (PHASE2)
- Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes (PHASE2)
- Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS (PHASE2,PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anakinra CI brief — competitive landscape report
- Anakinra updates RSS · CI watch RSS
- Biovitrum Ab portfolio CI